MiMedx Group, Inc. (MDXG) fair value analysis

Nasdaq · Updated 2026-09-07

MiMedx Group, Inc. is a regenerative medicine company that develops and distributes human cellular and tissue-based products for use in surgical and wound care applications. The company operates primarily in the United States, serving healthcare providers and patients through its portfolio of biological products.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, MDXG is trading at more than a 25% premium to estimated fair value.

MDXG currently ranks #106 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $4.27
Sector: Healthcare
12-month range: $3.58–$7.52

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range

What our data shows for MDXG

Our model validated 11 trailing price-to-earnings windows for MDXG, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $3.58–$7.52.
The 14-day relative strength index sits at a neutral 62.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MDXG
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MDXG news

TickrTrends' derived news-sentiment signal for MDXG is currently leaning positive, computed from recent coverage.

MDXG Maintains Buy Rating by Craig-Hallum -- Price Target Raised to $8.00 (gurufocus.com, 2026-08-27)
TickrTrends take: Craig-Hallum's maintained buy rating and raised price target for MDXG contrast with TickrTrends' current assessment that the Healthcare sector company is overvalued. A valuation-focused reader should monitor whether the analyst's increased confidence in the stock's prospects will narrow or widen the gap between market perception and TickrTrends' valuation metrics. The divergence between the buy recommendation and the overvalued designation suggests close attention to fundamental developments that could either justify upward revaluation or reinforce concerns about current pricing levels.
MDXG Looks 28.6% Undervalued on GF Value™ (gurufocus.com, 2026-08-27)
TickrTrends take: MDXG's GF Value analysis suggests the stock may have downside compression relative to its intrinsic worth estimate, which contrasts with TickrTrends' current overvalued assessment of the stock. A valuation-focused reader should monitor whether the GF Value methodology and TickrTrends' framework converge or continue to diverge, as the Healthcare sector can experience significant valuation adjustments based on pipeline developments and regulatory outcomes. The gap between these two valuation perspectives may indicate either an opportunity for value investors or reflect different assumptions about the company's future earnings power.
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) (manilatimes.net, 2026-08-11)
TickrTrends take: Sanara MedTech Inc., which trades under the ticker MDXG, released its unaudited second quarter 2026 financial results as a healthcare sector company currently assessed as overvalued by TickrTrends metrics. For investors focused on valuation, the key question is whether these quarterly results demonstrate sufficient earnings growth or margin expansion to justify the current market price relative to fundamental metrics. Readers should examine whether the company's revenue trajectory and profitability trends show meaningful improvement that could realign the stock with its valuation multiples.

What people are saying

Follow the MDXG conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MDXG stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MDXG is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is MDXG's TickrTrends verdict?

MDXG's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does MDXG compare to other Healthcare stocks?

MDXG ranks #106 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MDXG overbought or oversold?

MDXG's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MDXG vs ACAD · MDXG vs ALKS · MDXG vs AMGN · MDXG vs CDNA · MDXG vs DGX